Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 150351, 5 pages
http://dx.doi.org/10.1155/2014/150351
Research Article

Inhibition of Human Cytochrome P450 Enzymes by Allergen Removed Rhus verniciflua Stoke Standardized Extract and Constituents

Department of Medical Consilience, Graduate School, Dankook University, 152, Jukjeon-ro, Suji-gu, Yongin-si, Gyeonggi-do 448-701, Republic of Korea

Received 22 April 2014; Accepted 9 June 2014; Published 30 June 2014

Academic Editor: Mohamed Eddouks

Copyright © 2014 Hyunsik Jung and Sanghun Lee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Thomas-Schoemann, B. Blanchet, C. Bardin et al., “Drug interactions with solid tumour-targeted therapies,” Critical Reviews in Oncology/Hematology, vol. 89, no. 1, pp. 179–196, 2014. View at Publisher · View at Google Scholar
  2. C. D. Scripture and W. D. Figg, “Drug interactions in cancer therapy,” Nature Reviews Cancer, vol. 6, no. 7, pp. 546–558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. W. F. van Leeuwen, E. L. Swart, E. Boven, F. A. Boom, M. G. Schuitenmaker, and J. G. Hugtenburg, “Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method,” Annals of Oncology, vol. 22, no. 10, pp. 2334–2341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Giunta, “Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters: a review of the literature starting from a case report,” Case Reports in Medicine, vol. 2010, Article ID 426804, 4 pages, 2010. View at Publisher · View at Google Scholar
  5. A. K. Goey, J. H. Beijnen, and J. H. Schellens, “Herb-drug interactions in oncology,” Clinical Pharmacology & Therapeutics, vol. 95, no. 4, pp. 354–355, 2014. View at Google Scholar
  6. I. Meijerman, J. H. Beijnen, and J. H. M. Schellens, “Herb-drug interactions in oncology: focus on mechanisms of induction,” Oncologist, vol. 11, no. 7, pp. 742–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. W. Hwang, H. S. Han, K. Y. Lim, and J. Y. Han, “Drug interaction between complementary herbal medicines and gefitinib,” Journal of Thoracic Oncology, vol. 3, no. 8, pp. 942–943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Choi, H. Jung, K. Kim et al., “Rhus verniciflua stokes against advanced cancer: a perspective from the korean integrative cancer center,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 874276, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. S. Shin, Y. M. Park, J. H. Choi et al., “Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-κB in RAW 264.7 murine macrophage cells,” International Immunopharmacology, vol. 10, no. 8, pp. 943–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Lee, G. S. Jeong, B. Li, H. Park, and Y. Kim, “Anti-inflammatory effects of sulfuretin from Rhus verniciflua Stokes via the induction of heme oxygenase-1 expression in murine macrophages,” International Immunopharmacology, vol. 10, no. 8, pp. 850–858, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. D. Lee, J. E. Huh, G. Jeon et al., “Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models,” International Immunopharmacology, vol. 9, no. 3, pp. 268–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Kim, C. H. Jung, B. Jang et al., “Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from Rhus verniciflua stokes,” American Journal of Chinese Medicine, vol. 37, no. 3, pp. 609–620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. H. Kim, H. Y. Go, D. H. Jin et al., “Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines,” Cancer Letters, vol. 265, no. 2, pp. 197–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. H. Jung, J. H. Kim, M. H. Hong et al., “Phenolic-rich fraction from Rhus verniciflua Stokes (RVS) suppress inflammatory response via NF-κB and JNK pathway in lipopolysaccharide-induced RAW 264.7 macrophages,” Journal of Ethnopharmacology, vol. 110, no. 3, pp. 490–497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. O. Son, K. Y. Lee, J. C. Lee et al., “Selective antiproliferative and apoptotic effects of flavonoids purified from Rhus verniciflua Stokes on normal versus transformed hepatic cell lines,” Toxicology Letters, vol. 155, no. 1, pp. 115–125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. H. S. Jang, S. H. Kook, Y. O. Son et al., “Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells,” Biochimica et Biophysica Acta, vol. 1726, no. 3, pp. 309–316, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. I. T. Kim, Y. M. Park, K. M. Shin et al., “Anti-inflammatory and anti-nociceptive effects of the extract from Kalopanax pictus, Pueraria thunbergiana and Rhus verniciflua,” Journal of Ethnopharmacology, vol. 94, no. 1, pp. 165–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. K. T. Lim, C. Hu, and D. D. Kitts, “Antioxidant activity of a Rhus verniciflua Stokes ethanol extract,” Food and Chemical Toxicology, vol. 39, no. 3, pp. 229–237, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. S. D. Park, S. W. Lee, J. H. Chun, and S. H. Cha, “Clinical features of 31 patients with systemic contact dermatitis due to the ingestion of Rhus (lacquer),” British Journal of Dermatology, vol. 142, no. 5, pp. 937–942, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Choi, S. An, E. Kwon, W. Eo, and S. Lee, “Impact of standardized allergen-removed Rhus verniciflua stokes extract on advanced adenocarcinoma of the ampulla of Vater: a case series,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 203168, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Lee, K. Kim, H. Jung et al., “Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience,” Oncology, vol. 81, no. 5-6, pp. 312–318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. K. Lee, H. S. Jung, W. K. Eo, S. Y. Lee, S. H. Kim, and B. S. Shim, “Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases,” Annals of Oncology, vol. 21, no. 6, pp. 1383–1385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. H. Lee, W. C. Choi, K. S. Kim, J. W. Park, and S. W. Yoon, “Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua stokes extract,” Journal of Alternative and Complementary Medicine, vol. 16, no. 4, pp. 497–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. R. Kim, K. S. Kim, H. S. Jung, W. C. Choi, W. K. Eo, and S. H. Cheon, “A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua stokes extract,” Integrative Cancer Therapies, vol. 9, no. 1, pp. 100–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. H. Lee, K. S. Kim, W. C. Choi, and S. W. Yoon, “Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized rhus verniciflua stokes extract: a case study,” Explore, vol. 5, no. 4, pp. 242–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Ramasamy, L. V. Kiew, and L. Y. Chung, “Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents,” Molecules, vol. 19, no. 2, pp. 2588–2601, 2014. View at Publisher · View at Google Scholar
  27. N. A. Hanapi, J. Azizi, S. Ismail, and S. M. Mansor, “Evaluation of selected Malaysian medicinal plants on phase I drug metabolizing enzymes, CYP2C9, CYP2D6 and CYP3A4 activities in vitro,” International Journal of Pharmacology, vol. 6, no. 4, pp. 494–499, 2010. View at Google Scholar · View at Scopus
  28. M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, and D. C. Zeldin, “The human intestinal cytochrome P450 ‘pie’,” Drug Metabolism and Disposition, vol. 34, no. 5, pp. 880–886, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Lynch and A. Price, “The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects,” American Family Physician, vol. 76, no. 3, pp. 391–396, 2007. View at Google Scholar · View at Scopus
  30. D. Si, Y. Wang, Y. Zhou et al., “Mechanism of CYP2C9 inhibition by flavones and flavonols,” Drug Metabolism and Disposition, vol. 37, no. 3, pp. 629–634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Khan, D. N. Syed, N. Ahmad, and H. Mukhtar, “Fisetin: a dietary antioxidant for health promotion,” Antioxidants and Redox Signaling, vol. 19, no. 2, pp. 151–162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. P. G. Sand, A. Dreiseitel, M. Stang et al., “Cytochrome P450 2C19 inhibitory activity of common berry constituents,” Phytotherapy Research, vol. 24, no. 2, pp. 304–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Goldstein, “Clinical relevance of genetic polymorphisms in the human CYP2C subfamily,” British Journal of Clinical Pharmacology, vol. 52, no. 4, pp. 349–355, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kim, J. A. Johnson, and H. Derendorf, “Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms,” Journal of Clinical Pharmacology, vol. 44, no. 10, pp. 1083–1105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. F. Yang, H. W. Cui, T. Hasi, S. Q. Jia, M. L. Gong, and X. L. Su, “Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China,” Genetics and Molecular Research, vol. 9, no. 3, pp. 1844–1851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Osawa, K. K. Osawa, A. Miyaishi et al., “NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status,” Asian Pacific Journal of Cancer Prevention, vol. 8, no. 1, pp. 103–108, 2007. View at Google Scholar · View at Scopus
  37. I. Ayari, U. Fedeli, S. Saguem, S. Hidar, S. Khlifi, and S. Pavanello, “Role of CYP1A2 polymorphisms in breast cancer risk in women,” Molecular Medicine Reports, vol. 7, no. 1, pp. 280–286, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Lautraite, A. C. Musonda, J. Doehmer, G. O. Edwards, and J. K. Chipman, “Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1,” Mutagenesis, vol. 17, no. 1, pp. 45–53, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Lee, H. Lee, W. Choi et al., “Rhus verniciflua stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice,” Phytomedicine, vol. 16, no. 2-3, pp. 188–197, 2009. View at Publisher · View at Google Scholar · View at Scopus